Elite Pharmaceuticals (ELTP)

Executive Summary

Elite Pharmaceuticals is a U.S.-based specialty pharmaceutical company focused on developing, manufacturing, and marketing controlled-release generic drugs, with a particular emphasis on abuse-deterrent opioid formulations. Founded in 1997 and headquartered in Northvale, New Jersey, the company leverages its proprietary abuse-deterrent technology to differentiate its products in a competitive generic landscape. As of mid-2026, Elite has five commercial products and continues to file Abbreviated New Drug Applications (ANDAs) with the FDA, targeting opportunities in pain management and other therapeutic areas. The company's strategy involves both internal development and potential licensing or acquisition to expand its pipeline. Despite operating in a challenging generic pricing environment, Elite's focus on value-added formulations and niche markets provides a degree of resilience. The company's stock (OTC: ELTP) trades at a modest valuation of ~$366 million, reflecting both the potential of its pipeline and the risks inherent in generic drug development.

Upcoming Catalysts (preview)

• Q1 2027FDA Approval of Abuse-Deterrent Opioid ANDA (e.g., morphine or oxycodone)60% success
• Q3 2026Partnership or Licensing Agreement for New Generic Product40% success
• Q2 2027Positive Financial Results or Debt Reduction Announcement70% success